News & Analysis on Clinical Trial Services & Contract Research And Development
Strong demand for anti-cancer cytotoxic active pharmaceutical ingredients (APIs) has led Nicholas Piramal (NPIL) Pharma to upgrade infrastructure and hire more staff at its high potency substances (HPS) facility in Grangemouth.
Difficulties in identifying tablets have emerged as a major issue in a recent US survey of 150 pharmacists who are warning drugmakers that the lack of distinct appearance in pills leads in dispensing errors that cost more than 7,000 lives each year...
Thermo Electron has reported an operating profit growth of 26 per cent to $143.2m (€111.2m) and boosted its profit margin by three percentage points to 20 per cent in its second quarter results.
Two US contract research organisations (CROs), Averion and IT&E International, have joined to forces to specialise in the area of oncology services.
Fisher Scientific has reported a second-quarter pre-tax profit jump of 31 per cent to $146.1m (€113.4m), reflecting the success of recent acquisitions and operating initiatives.
Looking for $45m (€35m) in savings, Teva has decided to abandon its drug manufacturing plant in Cidra, Puerto Rico, as it scrambles to adjust capacity seven months after its acquisition of Ivax.
Contract research organisations (CROs) are slashing clinical trial times by an average of 30 per cent and the outsourcing trend is showing no signs of slowing, as the pharma industry continues to face rising pressure to reduce time-to-market of new drugs.
Sentry Logistic Solutions has launched an additional service, offering to build customised drug storage facilities for pharmaceutical companies with special needs.